

# Recommendations for cross-sectional imaging in cancer management, Third edition

## Preface

---

## Preface

Between 2016-2018, around 1,000 people a day were diagnosed with cancer in the UK.<sup>1</sup> Significant improvements in survival have been achieved as prevention, diagnosis and treatment have improved. In the 1970s, less than a quarter (23%) of cancer patients survived for 10 years. By 2010-11, that was closer to 50%.<sup>1</sup>

As a result, there has been a considerable increase in the number of patients living with cancer, currently estimated to be more than three million in the UK.<sup>2</sup>

Despite recent improvements in cancer care, survival rates in the UK lag behind other countries for certain cancers. Increasing demands on cancer diagnostics and late diagnosis are seen as key reasons for this.<sup>3</sup> In 2019, the NHS Long Term Plan was published with ambitions that by 2028, 75% of people with cancer will be diagnosed at an early stage (stage 1 or 2).<sup>4</sup> It is now clearly established that imaging is central to the management of patients with cancer throughout the patient pathway and will play a key role in supporting this target.

There is still a need to provide guidelines and protocols for computed tomography (CT) and magnetic resonance imaging (MRI) in cancer, with the objective of helping to achieve a high-quality, efficient and uniform cancer imaging service across the UK. A major advantage of adopting UK-wide protocols is the ability to provide a streamlined effective service in which appropriate scans are undertaken according to the patient's tumour type and purpose of the examination. These protocols will also ensure that imaging studies can be compared more accurately during follow-up in an individual patient, irrespective of where the patient has been imaged. This is particularly important for reducing the need to repeat imaging of patients being entered into clinical trials and also with the advent of imaging networks where scans may be read in varying locations.

CT and MRI are used at all stages of the patient pathway: diagnosis, staging, determining the appropriate therapy, including eligibility to enter into clinical trials, and during follow-up. They are used for the assessment of residual disease and for determining the presence and extent of tumour relapse. These key roles were recognised by previous editions of this manual, but guidelines and protocols need to be continually appraised and updated to keep abreast of technological advances and new therapeutic approaches so that optimum results can be achieved.

CT, MRI and PET are covered within these guidelines, reflecting the current clinical practice of using these complementary techniques. At different points along the patient pathway one or the other may be more appropriately used depending upon whether treatment intent is curative or palliative, and whether the imaging focus is for local or metastatic disease. These guidelines do not include ultrasound, although it is acknowledged that this imaging modality can play a significant role in cancer management.

These guidelines are intended to provide practical advice and recommendations for best practice which should be achievable for the majority of patients. However, they are not intended to be prescriptive and could be adapted readily to meet local requirements.

---

We have not included information on image interpretation which can be found in textbooks, journals and internet resources. We have tried to follow as closely as possible a standardised page layout, including reference to the TNM classification of tumours, where appropriate.

The Royal College of Radiologists has utilised the input of its affiliated Special Interest Groups<sup>5</sup> and nationally and internationally recognised radiologists with particular expertise in cancer imaging to produce these recommendations. I would like to thank all those who have contributed to the document for their hard work and dedication.

We hope that these protocols will be used widely within departments of radiology undertaking cancer imaging and will help to improve cancer services across the UK.

The guidelines are being published as individual chapters and over the coming months more chapters will be made available as they are published.

**Dr William Ramsden**

**Vice-President, Clinical Radiology**

**The Royal College of Radiologists**

## References

1. Cancer Research UK:  
[www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero](http://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk#heading-Zero)
  2. Macmillan Cancer Support:  
[www.macmillan.org.uk/\\_images/cancer-statistics-factsheet\\_tcm9-260514.pdf](http://www.macmillan.org.uk/_images/cancer-statistics-factsheet_tcm9-260514.pdf)
  3. Cancer Research UK:  
<https://news.cancerresearchuk.org/2019/09/11/measuring-up-how-does-the-uk-compare-internationally-on-cancer-survival/>
  4. NHS England: NHS Long Term Plan ambitions for cancer, 2019:  
[www.england.nhs.uk/cancer/strategy/](http://www.england.nhs.uk/cancer/strategy/)
  5. The Royal College of Radiologists, 2022:  
[www.rcr.ac.uk/clinical-radiology/networking/special-interest-groups-sigs](http://www.rcr.ac.uk/clinical-radiology/networking/special-interest-groups-sigs)
-

## Acknowledgements

This new work is an update of the previous publication and the RCR acknowledges with grateful thanks all those who contributed to the previous edition as well as all those who undertook this more recent updating work.

### 2006 contributors

Dr Juliet Britton  
 Dr Gina Brown  
 Dr Brendan Carey  
 Mrs Bernadette Cronin  
 Mr Steve Ebdon-Jackson  
 Dr Ashley Guthrie  
 Professor Janet Husband  
 Dr Michael King  
 Dr David MacVicar  
 Dr Kieran McHugh  
 Dr Anwar Padhani  
 Dr Sheila Rankin  
 Professor Rodney Reznek  
 Dr Bhupinder Sharma  
 Dr Paul Shrimpton  
 Mrs Kathlyn Slack  
 Dr John Spencer  
 Dr Sarah Swift

### 2014 contributors

Dr Clare Allen  
 Dr Sally Barrington  
 Dr Sue Barter  
 Dr Tim Beale  
 Dr Peter Britton  
 Dr Gina Brown  
 Dr Guy Burkill  
 Dr Bob Bury  
 Dr James Byrne  
 Dr Brendan Carey  
 Dr Sue Chua  
 Dr Steve Connor  
 Dr Phil Cook  
 Dr Sujal Desai  
 Mr Steve Ebdon-Jackson  
 Dr Julia Fairbairn  
 Dr Jo Fairhurst  
 Dr Fergus Gleeson  
 Dr Ruth Green  
 Dr Ashley Guthrie

Dr Clive Kay  
 Dr Andy Lowe  
 Dr Gitta Madani  
 Dr Kieran McHugh  
 Dr Julie Olliff  
 Dr Anwar Padhani  
 Dr Uday Patel  
 Dr Polly Richards  
 Dr Peter Riley  
 Dr Martin Rimmer  
 Dr Ashley Roberts  
 Prof Andrea Rockall  
 Dr Asif Saifuddin  
 Dr Evis Sala  
 Dr Andy Scarsbrook  
 Dr Maria Sheridan  
 Dr Aslam Sohaib  
 Dr Ben Taylor  
 Dr Rick Whitehouse  
 Dr Stuart Williams  
 Dr Wai-Lup Wong

## 2022 contributors

Professor Andy Scarsbrook  
 Dr Cindy Chew, on behalf of the British Society of Gastrointestinal Radiology (BSGAR)  
 Professor Stuart Taylor, on behalf of the British Society of Gastrointestinal Radiology (BSGAR)  
 Dr James Stephenson, on behalf of the British Society of Gastrointestinal Radiology (BSGAR)  
 Dr Raneem Albazaz, on behalf of the British Society of Gastrointestinal Radiology (BSGAR)  
 Dr Ashley Guthrie, on behalf of the British Society of Gastrointestinal Radiology (BSGAR)  
 Dr James Franklin, on behalf of the British Society of Gastrointestinal Radiology (BSGAR)  
 Dr Ashley Roberts, on behalf of the British Society of Gastrointestinal Radiology (BSGAR)  
 Dr Kieran Foley, on behalf of the British Society of Gastrointestinal Radiology (BSGAR)  
 (This list will be updated as more chapters are published).



The Royal College of Radiologists

The Royal College of Radiologists  
63 Lincoln's Inn Fields  
London WC2A 3JW

+44 (0)20 7405 1282

[enquiries@rcr.ac.uk](mailto:enquiries@rcr.ac.uk)

[www.rcr.ac.uk](http://www.rcr.ac.uk)

[@RCRadiologists](https://twitter.com/RCRadiologists)

The Royal College of Radiologists is a Charity  
registered with the Charity Commission No.  
211540

The Royal College of Radiologists. *Recommendations for cross-sectional imaging in cancer management, Third edition Preface.*  
London: The Royal College of Radiologists, 2022.

Ref No. BFCR(22)3

© The Royal College of Radiologists, April 2022.

This material has been produced by The Royal College of Radiologists (RCR) for use internally within the specialties of clinical oncology and clinical radiology in the United Kingdom. It is provided for use by appropriately qualified professionals, and the making of any decision regarding the applicability and suitability of the material in any particular circumstance is subject to the user's professional judgement.

While every reasonable care has been taken to ensure the accuracy of the material, RCR cannot accept any responsibility for any action taken, or not taken, on the basis of it. As publisher, RCR shall not be liable to any person for any loss or damage, which may arise from the use of any of the material. The RCR does not exclude or limit liability for death or personal injury to the extent only that the same arises as a result of the negligence of RCR, its employees, Officers, members and Fellows, or any other person contributing to the formulation of the material.

